



**CONVENTION ON  
BIOLOGICAL DIVERSITY**

Distr.  
GENERAL

UNEP/CBD/BSWG/3/Inf.1/Add.1  
13 October 1997

ORIGINAL : ENGLISH

OPEN-ENDED AD HOC WORKING  
GROUP ON BIOSAFETY  
Third Meeting  
Montreal, Canada  
13 to 17 October 1997

**DEFINITIONS FROM THE SUBMISSION OF MALAYSIA**

"advance informed agreement" the prior informed consent and agreement, with such conditions as appropriate, by the receiving country Party, through the national competent authority, regarding any intended transfer, handling or use of LMOs to or within the receiving country Party by the intending country Party, based on required information which is accurate, complete and current supplied by the intending country Party and/or person or entity under the intending country Party's jurisdiction, in advance of the intended activities.

"biosafety" the safe transfer, handling and use of any LMO resulting from biotechnology that may have adverse effect on the environment, in particular the conservation and sustainable use of biological diversity, socio-economic imperatives and the risks to agriculture and human health.

"centres of genetic diversity" the place or region where the source of diversity is located.

"Country of origin of genetic resources" the country which possesses those genetic resources in in-situ conditions.

"competent authority" the competent authority designated by parties to be the national competent authority in respect of the implementation of this protocol.

"contained use"	any operation involving organisms which are controlled by physical barriers or a combination of physical and/or chemical and/or biological barriers which limit their contact with, or their impacts on, the potentially receiving environment, which includes humans.
"deliberate release"	any release of LMOs that is not a contained use, including any intentional introduction of LMOs into the environment and/or the marketplace.
"living modified organisms"	organisms, other than human or human embryo, produced through genetic modification and whose genetic make-up is unlikely to occur in nature, including any genetic material intended for use to produce genetically modified organisms, and products derived therefrom, including genetically modified organisms which have been deregulated in any country.
"modern biotechnology"	a set of enabling techniques for bringing about specific man-made changes in the genetic material of organisms.
"risk"	the combination of the magnitude of the consequences of a hazard, if it occurs, and the likelihood that the consequences will occur.
"risk assessment"	the measures to estimate what harm might be caused, how likely it would occur and the scale of the estimated damage to the receiving country Party and its environment, in particular the conservation and sustainable use of biological diversity, socio-economic imperatives and the risks to agriculture and human health.
"risk management"	the strategies and measures to ensure that the transfer, handling and use of LMOs are safe, in accordance with Article 7.
"transfer"	includes the intentional transboundary movement of LMOs and the release of LMOs.
"unintended release"	any release which is not deliberate.
"user"	any person responsible for the development, production, use, handling, testing, marketing, transfer, release or distribution of LMOs but shall not include any member of the general public in the receiving country Party who purchases and/or uses an LMO.

- - - - -